EE05385B1 - LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon - Google Patents

LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon

Info

Publication number
EE05385B1
EE05385B1 EEP200300381A EEP200300381A EE05385B1 EE 05385 B1 EE05385 B1 EE 05385B1 EE P200300381 A EEP200300381 A EE P200300381A EE P200300381 A EEP200300381 A EE P200300381A EE 05385 B1 EE05385 B1 EE 05385B1
Authority
EE
Estonia
Prior art keywords
ákuiáhiváprotease
áamino
useunited
sulphonamides
benzothiazole
Prior art date
Application number
EEP200300381A
Other languages
English (en)
Estonian (et)
Inventor
Dominique�Louis�Nestor�Ghislain�Surleraux
Piet�Tom�Bert�Paul�Wigerinck
Daniel�Getman
Wim�Gaston�Verschueren
Sandrine�Marie�Helene�Vendeville
Marie-Pierre�T.M.M.G�De�Bethune
Jan�Octaaf�Antoon�De�Kerpel
Samuel�Leo�Christiaan�Moors
Herman�Augustinus�De�Kock
Marieke�Christiane�Johanna�Voets
Original Assignee
Tibotec�Pharmaceuticals�Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec�Pharmaceuticals�Ltd. filed Critical Tibotec�Pharmaceuticals�Ltd.
Publication of EE200300381A publication Critical patent/EE200300381A/xx
Publication of EE05385B1 publication Critical patent/EE05385B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200300381A 2001-02-14 2002-02-14 LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon EE05385B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01200529 2001-02-14
US28775801P 2001-05-02 2001-05-02
PCT/EP2002/001788 WO2002083657A2 (en) 2001-02-14 2002-02-14 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors

Publications (2)

Publication Number Publication Date
EE200300381A EE200300381A (et) 2003-12-15
EE05385B1 true EE05385B1 (et) 2011-02-15

Family

ID=26076833

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300381A EE05385B1 (et) 2001-02-14 2002-02-14 LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon

Country Status (30)

Country Link
US (1) US7659404B2 (cs)
EP (1) EP1370543B1 (cs)
JP (1) JP4530612B2 (cs)
KR (1) KR100870184B1 (cs)
CN (2) CN101230067B (cs)
AP (1) AP1504A (cs)
AT (1) ATE343567T1 (cs)
AU (1) AU2002302363B2 (cs)
BG (1) BG66301B1 (cs)
BR (1) BR0207862A (cs)
CA (1) CA2438304C (cs)
CY (1) CY1108073T1 (cs)
CZ (1) CZ304273B6 (cs)
DE (1) DE60215623T2 (cs)
DK (1) DK1370543T3 (cs)
EA (1) EA006096B1 (cs)
EE (1) EE05385B1 (cs)
ES (1) ES2275866T3 (cs)
HR (1) HRP20030735B1 (cs)
HU (1) HU229224B1 (cs)
IL (2) IL157171A0 (cs)
MX (1) MXPA03007236A (cs)
NO (1) NO326174B1 (cs)
NZ (1) NZ527391A (cs)
PL (1) PL213327B1 (cs)
PT (1) PT1370543E (cs)
SI (1) SI1370543T1 (cs)
SK (1) SK287582B6 (cs)
WO (1) WO2002083657A2 (cs)
ZA (1) ZA200306086B (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2374215C (en) 1999-05-28 2011-05-24 Virco N.V. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US20040073378A1 (en) 2000-10-20 2004-04-15 Dehertogh Pascale Alfons Rosa Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
AU2002302363B2 (en) 2001-02-14 2008-05-01 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
WO2003057173A2 (en) 2002-01-07 2003-07-17 Sequoia Pharmaceuticals Broad spectrum inhibitors
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
ATE397669T1 (de) 2002-07-01 2008-06-15 Tibotec Pharm Ltd Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase
ATE432506T1 (de) 2002-07-01 2009-06-15 Tibotec Pharm Ltd Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
WO2004014371A1 (en) * 2002-08-02 2004-02-19 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors
JP4879484B2 (ja) * 2002-08-02 2012-02-22 テイボテク・フアーマシユーチカルズ・リミテツド 広スペクトルの2−アミノ−ベンゾチアゾールスルホンアミドhivプロテアーゼ阻害剤
US20070123574A1 (en) * 2003-09-30 2007-05-31 De Kock Herman A Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
WO2005110428A2 (en) * 2004-05-07 2005-11-24 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
RU2421459C2 (ru) 2005-02-25 2011-06-20 Тиботек Фармасьютикалз Лтд. Синтез предшественника ингибитора протеазы
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
JO2841B1 (en) * 2006-06-23 2014-09-15 تيبوتيك فارماسيوتيكالز ليمتد 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV)
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
JO3090B1 (ar) * 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
US9024038B2 (en) * 2010-12-27 2015-05-05 Purdue Research Foundation Compunds and methods for treating HIV
RU2014115227A (ru) 2012-04-20 2015-10-27 Джилид Сайэнс, Инк. Производные бензотиазол-6-ил уксусной кислоты и их примение для лечения вич-инфекции
CN104000824B (zh) * 2014-05-28 2016-07-06 中山大学 苯并五元杂环类化合物在制备抗hiv-1病毒药物中的应用
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
CN116354903B (zh) * 2021-12-28 2025-09-09 南京药石科技股份有限公司 一种6-苯并噻唑磺酰氯的制备方法
WO2024206093A1 (en) * 2023-03-24 2024-10-03 Purdue Research Foundation Hiv-1p rotease inhibitors and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0445926B1 (en) 1990-03-09 1996-08-21 Milliken Research Corporation Organic materials having sulfonamido linked poly(oxyalkylene) moieties and their preparation
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2140929C (en) * 1992-08-25 2006-09-12 Michael L. Vazquez Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
ATE174587T1 (de) * 1993-08-24 1999-01-15 Searle & Co Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
CN1110300C (zh) 1993-10-01 2003-06-04 阿斯特拉公司 工艺技术ⅰ
US6143747A (en) 1995-01-20 2000-11-07 G. D. Searle & Co. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US5756533A (en) 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6140505A (en) 1995-03-10 2000-10-31 G. D. Searle & Co. Synthesis of benzo fused heterocyclic sulfonyl chlorides
US6861539B1 (en) * 1995-03-10 2005-03-01 G. D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6143788A (en) * 1995-03-10 2000-11-07 G.D. Searle & Co. Bis-amino acid hydroxyethlamino sulfonamide retroviral protease inhibitors
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
PL184771B1 (pl) 1995-03-10 2002-12-31 Searle & Co Związek stanowiący hydroksyetyloaminosulfonamid pirolidynokarbonyloaminokwasu, kompozycja zawierająca ten związek, jego zastosowanie do wytwarzania kompozycji do leczenia infekcji retrowirusowej i sposób zapobiegania replikacji retrowirusa in vitro
WO1997018205A1 (en) 1995-11-15 1997-05-22 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
EP0904060B1 (en) 1996-05-20 2003-12-10 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
PL190566B1 (pl) 1997-03-26 2005-12-30 Janssen Pharmaceutica Nv Peletka, zawierająca rdzeń pokryty itrakonazolem i polimerem i sposób jej wytwarzania oraz postać dawki farmaceutycznej
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
JP2001527062A (ja) * 1997-12-24 2001-12-25 バーテックス ファーマシューティカルズ インコーポレイテッド アスパルチルプロテアーゼインヒビターのプロドラッグ
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
CA2335477C (en) * 1998-06-19 2010-11-30 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
AU4828199A (en) 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
AU771780B2 (en) 1998-06-23 2004-04-01 Board Of Trustees Of The University Of Illinois, The Fitness assay and associated methods
AR031520A1 (es) 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
AU2002302363B2 (en) 2001-02-14 2008-05-01 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors

Also Published As

Publication number Publication date
NO326174B1 (no) 2008-10-13
EP1370543B1 (en) 2006-10-25
ES2275866T3 (es) 2007-06-16
WO2002083657A3 (en) 2003-02-13
ZA200306086B (en) 2005-01-26
BG108143A (en) 2004-07-30
IL157171A (en) 2012-10-31
PT1370543E (pt) 2007-02-28
PL363778A1 (en) 2004-11-29
EE200300381A (et) 2003-12-15
SK11022003A3 (sk) 2004-07-07
AP2003002856A0 (en) 2003-09-30
AU2002302363B2 (en) 2008-05-01
HK1061233A1 (en) 2004-09-10
BG66301B1 (bg) 2013-03-29
HU229224B1 (en) 2013-09-30
SI1370543T1 (sl) 2007-04-30
EA006096B1 (ru) 2005-08-25
AP1504A (en) 2005-12-10
JP4530612B2 (ja) 2010-08-25
CY1108073T1 (el) 2014-02-12
CA2438304C (en) 2011-04-12
ATE343567T1 (de) 2006-11-15
MXPA03007236A (es) 2003-12-04
PL213327B1 (pl) 2013-02-28
US20040116485A1 (en) 2004-06-17
BR0207862A (pt) 2004-06-22
EA200300891A1 (ru) 2004-02-26
CZ20032415A3 (cs) 2004-04-14
HRP20030735A2 (en) 2005-08-31
EP1370543A2 (en) 2003-12-17
NZ527391A (en) 2005-04-29
HUP0303257A2 (hu) 2004-01-28
WO2002083657A2 (en) 2002-10-24
NO20033584L (no) 2003-10-14
US7659404B2 (en) 2010-02-09
CA2438304A1 (en) 2002-10-24
HRP20030735B1 (en) 2012-02-29
CN101230067B (zh) 2011-06-15
KR100870184B1 (ko) 2008-11-24
SK287582B6 (sk) 2011-03-04
DE60215623D1 (de) 2006-12-07
IL157171A0 (en) 2004-02-08
DK1370543T3 (da) 2007-02-19
CN100369904C (zh) 2008-02-20
DE60215623T2 (de) 2007-08-30
KR20030077017A (ko) 2003-09-29
CZ304273B6 (cs) 2014-02-12
CN101230067A (zh) 2008-07-30
JP2004518767A (ja) 2004-06-24
NO20033584D0 (no) 2003-08-13
CN1525962A (zh) 2004-09-01

Similar Documents

Publication Publication Date Title
EE05385B1 (et) LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon
NO20033556D0 (no) Farmasöytiske preparater
DK1478339T3 (da) Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
NO20033384D0 (no) Farmasöytisk formulering
IS7714A (is) Lyfjasamsetningar úr módafíníl
NO20040282L (no) Hepatit C virus-polymerase-inhibitorer, samt anvendelse og fremgangsmåte for fremstilling derav og farmasøytisk preparat
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
NO20033785L (no) Farmasöytisk formulering
KR20050009999A (ko) 약제학적 제제
NO20044192L (no) 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20041272L (no) Tetracycline derivatives and methods of use thereof
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
NO20044916L (no) Preparater av sulfinylacetamid
NO20035627D0 (no) Farmasöytisk formulering
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20033506L (no) Parasitticidale preparater og metoder for anvendelse
NO20035328D0 (no) Nye forbindelser og preparater som katepsinhibitorer
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
EE200300501A (et) Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
IS2707B (is) Nýjar lyfjasamsetningar úr módafíníli
EE05384B1 (et) LaiaspektrilisedÁ2-(asendatudÁamino)bensoksasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁkasutamine,ÁfarmatseutilineÁkompositsioonÁjaÁmeetodÁretroviiruseÁreplikatsiooniÁinhibeerimiseks
DK1407780T3 (da) Farmaceutisk stabile hæmostatiske præparater
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir

Legal Events

Date Code Title Description
HE1A Change of address
HE1A Change of address
MM4A Lapsed by not paying the annual fees

Effective date: 20160214